Answers are grounded in this paper and cite their sources.
Background: The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease is well recognized. However, the prevalence of MetS among patients with non-alcoholic fatty liver disease in different studies varied considerably. Moreover, an up-to-date and pooled estimate of MetS in that group is limited. Therefore, this systematic review and meta-analysis aimed to estimate the pooled prevalence of metabolic syndrome among patients with non-alcoholic fatty liver disease. Objective: To estimate the pooled prevalence of metabolic syndrome among patients with non-alcoholic fatty liver disease. Design: Systematic review and meta-analysis. Data source and methods: This systematic review and meta-analysis included original articles published in English. Multiple databases, including PubMed, Google Scholar, Web of Science, and Cochrane Library, were searched to identify all relevant publications. A random-effects model was used to obtain the pooled estimate. Statistical heterogeneity was assessed using the Cochrane Q test and the I 2 statistic. Funnel plot and Egger’s regression statistical test were utilized to measure publication bias. This systematic review and meta-analysis were based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. Result: Initially, a total of 1432 articles were retrieved using electronic databases. After duplication removal, title/abstract screening, and eligibility assessment, 9 studies (12 prevalence estimates) were selected for review. The random effect model indicated that the pooled prevalence of MetS among non-alcoholic fatty liver disease patients was 38% (95% CI: 29–48). Subgroup analysis by MetS diagnostic criteria indicated that the pooled prevalence was 40% (95% CI: 29–52) in NCEP/ATP III criteria-based studies and 32% (95% CI: 29–36) in International Diabetic Federation (IDF) criteria-based studies, respectively. Additionally, subgroup analysis by WHO region also showed that the pooled prevalence ranged from 33% to 47% in the Southeast Asia region and the Eastern Mediterranean region. The visual funnel plot did not suggest asymmetry, and the Eggers test did not indicate publication bias. Conclusion: The findings of this review indicated that a substantial number of people are affected by MetS among patients who have non-alcoholic fatty liver disease. An effective prevention strategy to mitigate morbidity and mortality associated with MetS is recommended.
No takes yet. Share an insight, caveat, or question.
Bewket et al. (2026) studied this question.